Pfizer beats by $0.04, beats on revs; raises FY15 guidance
- Reports Q2 (Jun) earnings of $0.56 per share, excluding non-recurring items, $0.04 better than the Capital IQ Consensus Estimate of $0.52; revenues fell 7.2% year/year to $11.85 bln vs the $11.42 bln consensus, which reflects operational growth of $125 million, or 1%, more than offset by the unfavorable impact of foreign exchange of $1.0 billion, or 8%. Excluding the impact of foreign exchange, adjusted diluted EPS(2) increased by approximately 6%.
- Co issues in-line guidance for FY15, raises EPS to $2.01-2.07, excluding non-recurring items, from $1.95-2.05 vs. $2.06 Capital IQ Consensus; raises FY15 revs to $45-46 bln from $44-46 bln vs. $45.96 bln Capital IQ Consensus Estimate.